First-in-Human Trial of Oral AN2-502998
← catalyst calendarSponsored by AN2 Therapeutics, Inc (industry) · ANTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Double · Basic science
Enrollment
72actual
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-04 | actual | When the study began enrolling |
| Primary completion | 2026-03-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-03-14 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: AN2-502998
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFEvaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion for a Single Dose
measured Day 1 through last follow-up (9 Days after single dose)
Evaluate Physical Examination Abnormalities from Baseline Through Study Completion for a Single Dose
measured Day 1 through last follow-up (9 Days after single dose)
Evaluate Change in Vital Signs from Baseline Through Study Completion for a Single Dose
measured Day 1 through last follow-up (9 Days after single dose)
Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion for a Single Dose
measured Day 1 through last follow-up (9 Days after single dose)
Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion for a Single Dose
measured Day 1 through last follow-up (9 Days after single dose)
Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion for Multiple Doses
measured Day 1 through last follow-up (10 Days after last dose)
Evaluate Physical Examination Abnormalities from Baseline Through Study Completion for Multiple Doses
measured Day 1 through last follow-up (10 Days after last dose)
Evaluate Change in Vital Signs from Baseline Through Study Completion for Multiple Doses
measured Day 1 through last follow-up (10 Days after last dose)
Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion for Multiple Doses
measured Day 1 through last follow-up (10 Days after last dose)
Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion for Multiple Doses
measured Day 1 through last follow-up (10 Days after last dose)
Characterize the PK Profile of AN2-502998: Maximum Plasma Concentration
measured Day 1 through last follow-up (3 Days after last dose)
Characterize the PK Profile of AN2-502998: Time to Maximum Plasma Concentration
measured Day 1 through 3 days after last dose
Characterize the PK Profile of AN2-502998: Terminal Half-Life
measured Day 1 through 3 days after last dose
Characterize the PK Profile of AN2-502998: Area Under Plasma Concentration Curve
measured Day 1 through 3 days after last dose
Characterize the PK Profile of AN2-502998: Apparent Plasma Clearance
measured Day 1 through 3 days after last dose
Permalink · ANTX's whole pipeline · Catalyst calendar · Every registered study · What changed